Clinical Trials Browser

Phase 2/3 × Duloxetine Hydrochloride × 90 days × Clear all

NCT04137107 2026-01-26

Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer

Phase 2/3 Active not recruiting

Gastrointestinal

Colorectal Neoplasms